Journal of Pulmonology and Respiratory Diseases
Open Access

Asthma; Pathophysiology; Bronchodilators; Inflammation; Immune mechanisms; Personalized medicine

Introduction

Asthma is a chronic respiratory condition that causes inflammation and narrowing of the airways, leading to symptoms such as wheezing, shortness of breath, and coughing. Historically, asthma has been recorded in various cultures, but its mechanisms were not understood until the advent of modern medicine. In ancient times, asthma was described in texts such as the Ebers Papyrus, dating back to 1550 BC in Egypt, where it was referred to as "air hunger" [1]. The condition was seen more as an episodic problem, with treatments involving herbal remedies and rituals aimed at expelling "bad air." It wasn't until the 19th century that asthma began to be studied in more depth, particularly with the development of respiratory physiology. With the introduction of the stethoscope in 1816, physicians could more effectively diagnose asthma and distinguish it from other respiratory disorders [2]. The recognition of asthma as a distinct clinical entity came in the 19th century, and the term "asthma" was widely adopted. The 20th century marked significant advances in the understanding of asthma's pathophysiology. Research revealed that asthma was primarily an inflammatory disease with various triggers, including allergens, infections, and environmental factors [3]. The discovery of bronchial hyperresponsiveness and airway remodeling further contributed to our understanding of the disease's progression. The identification of the immune system’s role, particularly the involvement of mast cells, eosinophils, and T-helper 2 (Th2) cells, brought clarity to the mechanisms behind asthma attacks. The development of medications, such as bronchodilators and corticosteroids, significantly improved asthma management [4]. Today, asthma treatment has evolved with the advent of targeted biologics and personalized medicine. New therapies targeting specific cytokines, such as interleukins (IL-4, IL-5, IL-13), have revolutionized asthma treatment, offering more effective, individualized care [5]. This review highlights the historical journey of asthma, the scientific breakthroughs that have shaped our current understanding, and the promising future of asthma management.

Results

Over the years, asthma research has led to a significant understanding of its mechanisms and treatment strategies. Initially, the primary treatment options for asthma included non-specific bronchodilators and general anti-inflammatory therapies. However, with advancements in immunology and pharmacology, asthma management evolved to target the specific pathways involved in its pathogenesis. One of the major breakthroughs was the discovery of bronchial hyperresponsiveness (BHR), which indicated that the airways in asthmatic individuals were more sensitive to stimuli such as allergens, cold air, and pollutants. This discovery led to the use of bronchodilators, such as beta-agonists, to provide symptomatic relief by relaxing the airway muscles. Research also elucidated the role of inflammation in asthma, with the identification of T-helper 2 (Th2) cell-mediated immune responses being central to its pathophysiology. This finding led to the development of corticosteroids, which suppress inflammation and reduce the frequency of asthma attacks. The introduction of biologic therapies has further revolutionized asthma treatment, particularly for patients with severe, uncontrolled asthma. Monoclonal antibodies targeting specific inflammatory cytokines, such as interleukin-5 (IL-5) and interleukin-4 (IL-13), have demonstrated efficacy in reducing exacerbations and improving lung function. Personalized medicine, recognizing distinct asthma phenotypes, has allowed for more precise treatments. Newer drugs, like biologics, have led to significant improvements in the quality of life for individuals with severe asthma.

Discussion

Asthma's evolution from a mysterious ailment to a well-understood disease has been a long and transformative journey. Early treatments were largely empirical, relying on herbal remedies and traditional practices. The scientific understanding of asthma began to take shape with advancements in respiratory physiology, but it wasn’t until the 20th century that key immunological insights were gained. These discoveries laid the foundation for modern treatment strategies [6]. The concept of inflammation as a central feature of asthma was revolutionary. The identification of the immune cells involved, such as mast cells, eosinophils, and T-helper 2 (Th2) cells, allowed for a deeper understanding of how asthma attacks occur. This discovery led to the development of corticosteroids and bronchodilators, which helped to manage symptoms and reduce inflammation. While these medications greatly improved asthma care, they were not a cure, and some patients continued to experience exacerbations [7]. Biologic therapies have since emerged as game-changers, particularly for individuals with severe asthma who do not respond well to traditional treatments. Targeted biologics, including monoclonal antibodies, can inhibit specific cytokines, such as IL-4, IL-5, and IL-13, involved in the inflammatory process. This targeted approach has led to improvements in asthma control, reducing hospitalizations, exacerbations, and symptoms. Additionally, personalized medicine, which takes into account the distinct phenotypes and endotypes of asthma, has allowed for more effective and individualized care. While current treatments are highly effective, challenges remain in asthma management [8]. The heterogeneity of asthma requires ongoing research to identify new targets for therapy and improve the understanding of its molecular mechanisms.

Conclusion

The history of asthma, from ancient Egypt to the present day, reflects significant advancements in our understanding and treatment of the disease. What was once a mysterious condition is now recognized as a complex, multifactorial disorder with distinct pathophysiological mechanisms. Research into asthma’s inflammatory pathways and immune responses has provided crucial insights into its underlying mechanisms, leading to more effective therapies. Bronchodilators and corticosteroids marked the first major steps in asthma management, providing symptom relief and reducing inflammation. However, the real revolution in treatment came with the advent of biologics, which target specific immune pathways. Monoclonal antibodies that inhibit cytokines like IL-5 and IL-13 have provided significant improvements for patients with severe asthma, reducing exacerbations and improving overall lung function. Personalized medicine represents the next frontier in asthma treatment. By recognizing the different phenotypes and endotypes of asthma, clinicians can now tailor therapies to individual patients, ensuring more effective and targeted interventions. This approach has already shown great promise in improving outcomes for those with difficult-to-control asthma. Despite the advances in treatment, asthma remains a global health challenge, particularly in low-resource settings where access to medications and healthcare is limited. Ongoing research is essential to further unravel the molecular mechanisms of asthma, leading to even more refined and effective treatments. With continuous advancements, asthma management is expected to continue evolving, improving the quality of life for individuals affected by this chronic condition.

References

1. Kishaba T, Nagano H, Nei Y, Yamashiro S (2016) Body mass index-percent forced vital capacity-respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients. J Thorac Dis 8: 3596-3604.

Indexed at, Google Scholar, Crossref

2. Moon SW, Choi JS, Lee SH, Jung KS, Jung JY, et al. (2019) Thoracic skeletal muscle quantification: low muscle mass is related with worse prognosis in idiopathic pulmonary fibrosis patients. Respir Res 20: 35.

Indexed at, Google Scholar, Crossref

3. Nakano A, Ohkubo H, Taniguchi H, Kondoh Y, Matsuda T, et al. (2020) Early decrease in erector spinae muscle area and future risk of mortality in idiopathic pulmonary fibrosis. Sci Rep 10: 2312.

Indexed at, Google Scholar, Crossref

4. Jouneau S, Rousseau C, Lederlin M, Lescoat A, Kerjouan M, et al. (2022) Malnutrition and decreased food intake at diagnosis are associated with hospitalization and mortality of idiopathic pulmonary fibrosis patients. Clin Nutr 41: 1335-1342.

Indexed at, Google Scholar, Crossref

5. Tracey KJ, Wei H, Manogue KR, Fong Y, Hesse DG, et al. (1998) Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med 167: 1211-1227.

Indexed at, Google Scholar, Crossref

6. Durheim MT, Judy J, Bender S, Neely ML, Baumer D, et al. (2020) A retrospective study of in-hospital mortality in patients with idiopathic pulmonary fibrosis between 2015 and 2018. Medicine (Baltimore) 99: 23143.

Indexed at, Google Scholar, Crossref

7. Kim HJ, Snyder LD, Adegunsoye A, Neely ML, Bender S, et al. (2021) Hospitalizations in patients with idiopathic pulmonary fibrosis. Respir Res 22: 257.

Indexed at, Google Scholar, Crossref

8. Durheim MT, Judy J, Bender S, Baumer D, Lucas J, et al. (2019) In-Hospital Mortality in Patients with Idiopathic Pulmonary Fibrosis: A US Cohort Study. Lung 197: 699-707.

Indexed at, Google Scholar, Crossref